TLR4 and cancer: A major endogenous TLR4 agonist, that is relevant to cancer, is the DAMP high-mobility group box 1 (HMGB1), which possesses protumour characteristics through sustaining an anti-inflammatory environment and promoting invasion metastasis and angiogenesis [15].